Seoul National University Hospital
Seoul, 03080, South Korea
NCT Number: NCT02864446
Urinary intestinal fatty acid binding protein (i-FABP), a marker of intestinal mucosal cell damage, has recently been proposed as a clinically useful measure in the early detection of necrotizing enterocolitis (NEC). However, there are no data on urinary i-FABP in meconium obstruction of prematurity (MOP). This study aimed to evaluate urinary i-FABP in MOP patient as a marker for early detection.
Looking for future studies?
Notify MeUp to 36 week
All sexes
Observational
Seoul, 03080, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: within 48 hours after birth
Time frame: through study completion (an average of 1 month)
Time frame: within 48 hours after birth
Time frame: within 48 hours after birth
Time frame: within 48 hours after birth
Time frame: within 48 hours after birth
Seoul National University Hospital
Other
The Clinical Utility of Urine Intestinal Fatty Acid Binding Protein in the Management of Very Low Birth Weight Infants With Meconium Obstruction
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03513640
Digestive System Diseases, Gastrointestinal Diseases
Seoul, South Korea
View Trial DetailsNCT06048614
Digestive System Diseases, Gastrointestinal Diseases
Singapore
View Trial DetailsNCT04713579
Atresia; Bowel, Bowel Obstruction
Manchester, United Kingdom
View Trial DetailsNCT04020939
Colonic Diseases, Congenital Abnormalities
Montreal, Quebec, Canada
View Trial Details